Analysts expect that Audentes Therapeutics Inc (NASDAQ:BOLD) will report ($1.08) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Audentes Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.23) and the highest estimate coming in at ($0.98). Audentes Therapeutics reported earnings of ($0.97) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 11.3%. The firm is expected to announce its next quarterly earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Audentes Therapeutics will report full year earnings of ($4.25) per share for the current fiscal year, with EPS estimates ranging from ($4.67) to ($3.64). For the next financial year, analysts forecast that the business will report earnings of ($4.38) per share, with EPS estimates ranging from ($5.03) to ($3.39). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Audentes Therapeutics.
Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.08) by $0.07. During the same quarter in the prior year, the company posted ($0.85) earnings per share.
In other news, Director Louis G. Lange sold 21,000 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $37.79, for a total value of $793,590.00. Following the completion of the sale, the director now directly owns 290,001 shares of the company’s stock, valued at approximately $10,959,137.79. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Matthew R. Patterson sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $34.04, for a total transaction of $680,800.00. Following the completion of the sale, the chief executive officer now directly owns 135,368 shares of the company’s stock, valued at $4,607,926.72. The disclosure for this sale can be found here. Insiders own 5.30% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in BOLD. Meeder Asset Management Inc. raised its holdings in shares of Audentes Therapeutics by 578.5% during the second quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 619 shares during the period. Aperio Group LLC acquired a new stake in shares of Audentes Therapeutics during the second quarter valued at approximately $46,000. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Audentes Therapeutics during the fourth quarter valued at approximately $92,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Audentes Therapeutics by 50.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 1,005 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Audentes Therapeutics by 34.5% during the fourth quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 1,700 shares during the period. 96.72% of the stock is owned by institutional investors and hedge funds.
Shares of BOLD traded up $0.93 during midday trading on Friday, hitting $33.88. The company had a trading volume of 334,055 shares, compared to its average volume of 511,680. The company’s 50 day moving average price is $37.03 and its 200 day moving average price is $35.88. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -9.96 and a beta of 1.70. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $41.65.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Further Reading: How to build a Fibonacci channel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.